Susquehanna International Group, LLP Revance Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$2.57 - $2.57 $58,082 - $58,082	-22,600 Reduced 47.18%	25,300 $65,000
Q2 2024 Aug 15, 2024	SELL	$2.34 - $4.73 $471,510 - $953,095	-201,500 Reduced 80.79%	47,900 $123,000
Q1 2024 May 07, 2024	BUY	$4.65 - $9.31 $628,680 - $1.26 Million	135,200 Added 118.39%	249,400 $1.23 Million
Q4 2023 Feb 14, 2024	SELL	$5.81 - $11.2 $471,190 - $908,320	-81,100 Reduced 41.53%	114,200 $1 Million
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $700,817 - $1.53 Million	61,100 Added 45.53%	195,300 $2.24 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $753,350 - $1.15 Million	30,500 Added 29.41%	134,200 $3.4 Million
Q1 2023 May 16, 2023	BUY	$18.36 - $35.27 $530,604 - $1.02 Million	28,900 Added 38.64%	103,700 $3.34 Million
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $1.4 Million - $2.34 Million	-76,300 Reduced 50.5%	74,800 $1.38 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $517,313 - $1.03 Million	36,100 Added 31.39%	151,100 $4.08 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.